Faculty, Staff and Student Publications
Publication Date
2-1-2024
Journal
JTO Clinical and Research Reports
Abstract
INTRODUCTION: NSCLC transformation to SCLC has been best characterized with
METHODS: In this study, we conducted a single-center retrospective analysis of clinical and genomic characteristics of patients with
RESULTS: A total of 34 patients were identified in our study. Median age at initial diagnosis was 58, and median time to SCLC transformation was 24.2 months. 68% were female and 82% were never smokers. 79% of patients were diagnosed as stage IV disease, and over half had brain metastases at baseline. Median overall survival of the entire cohort was 38.3 months from initial diagnoses and 12.4 months from time of SCLC transformation. Most patients harbored
CONCLUSIONS: SCLC transformation is a potential treatment resistance mechanism in driver-mutant NSCLC. In our cohort of 34
Keywords
Histologic transformation, SCLC, NSCLC, Resistance mechanism, Osimertinib, Cell surface target
DOI
10.1016/j.jtocrr.2023.100623
PMID
38357092
PMCID
PMC10864847
PubMedCentral® Posted Date
December 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons
Comments
Supplementary Material
PMID: 38357092